Bluebird Bio, Celgene Hatch Gene Therapy Collaboration

Privately held gene therapy company bluebird bio soared to new heights in a discovery, development and commercialization deal with big biotech Celgene Corp. to use its technology to genetically modify a patient's own T cells to target and destroy cancer cells. The multiyear R&D collaboration has the potential to generate multiple products based on the modified cells, known as chimeric antigen receptor (CAR) T cells.